The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects
| Autor: | Tran Khac Dien, C. A. A. Van Der Graaf, C. J. van Boxtel, M. A. van Agtmael, Richard P. Koopmans |
|---|---|
| Přispěvatelé: | Internal medicine, AII - Infectious diseases, AII - Inflammatory diseases, CCA - Cancer Treatment and quality of life |
| Rok vydání: | 1998 |
| Předmět: |
Adult
Male medicine.medical_treatment Cmax Dihydroartemisinin Administration Oral Biological Availability Pharmacology Methylation Mixed Function Oxygenases Antimalarials Pharmacokinetics Cytochrome P-450 Enzyme System medicine Humans Pharmacology (medical) Artemether Artemisinin Omeprazole Active metabolite Cross-Over Studies Gastric emptying Chemistry Anti-Ulcer Agents Quinidine Artemisinins Cytochrome P-450 CYP2C19 Cytochrome P-450 CYP2D6 Area Under Curve Aryl Hydrocarbon Hydroxylases Sesquiterpenes medicine.drug |
| Zdroj: | Van Agtmael, M A, Van der Graaf, C A A, Dien, T K, Koopmans, R P & Van Boxtel, C J 1998, ' The contribution of the enzymes CYP2D6 and CYP2C19 in the demethylation of artemether in healthy subjects ', European Journal of Drug Metabolism and Pharmacokinetics, vol. 23, no. 3, pp. 429-436 . https://doi.org/10.1007/BF03192305 European Journal of Drug Metabolism and Pharmacokinetics, 23(3), 429-436. Springer Paris |
| ISSN: | 0378-7966 |
| DOI: | 10.1007/BF03192305 |
| Popis: | The contribution of the enzymes CYP2D6 and CYP2C19 to the metabolism of artemether was evaluated in a cross-over study in seven healthy adult Caucasian subjects. The pharmacokinetic properties of artemether and its active metabolite dihydroartemisinin were compared when given 100 mg artemether orally alone or in combination with either CYP2D6-inhibitor quinidine or CYP2C19-inhibitor omeprazole. Plasma concentrations of artemether and dihydroartemisinin were measured with reversed phase high performance liquid chromatography with electro-chemical detection (HPLC-ED). Artemether was rapidly absorbed with a mean t(max) of 0.8 h (95% confidence interval, CI = 0.5-1.1) reaching a mean C(max) of 29 ng/ml (14-45 ng/ml). The mean elimination half-life was 1.3 h (0.8-1.8 h). The pharmacokinetic parameters for dihydroartemisinin were not significantly different from those for artemether. Artemether combined with quinidine revealed no significant changes in the plasma concentrations of either artemether or dihydroartemisinin. No changes were seen in the combination with omeprazole as a CYP2C19 inhibitor. A second peak in the plasma concentration profile was observed 2-4 h after drug intake. This phenomenon was possibly related to variable gastric emptying. No major contribution of the enzymes CYP2D6 or CYP2C19 was found in artemether metabolism. No interethnic differences in artemether metabolism on the basis of a genetic polymorphism of these enzymes is to be expected. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink